At The University of Texas MD Anderson Cancer Center in Houston, researchers have identified a genetic fingerprint in tumor cells that could help doctors predict which men with advanced prostate cancer will benefit most from a powerful combination of immune-boosting drugs—a breakthrough that matters enormously for patients facing one of medicine's toughest cancers.
Metastatic castration-resistant prostate cancer, or mCRPC, develops when the disease spreads beyond the prostate and becomes resistant to hormone treatments. It represents a cruel turning point in the illness: the cancer has learned to survive standard approaches. For years, chemotherapy was the only option left, yet many patients still saw their disease progress. Now, researchers led by Dr. Padmanee Sharma, a professor of Genitourinary Medical Oncology at the Allison Institute, have shown that a combination of two immune checkpoint inhibitors—ipilimumab and nivolumab—can help a subset of these patients achieve lasting responses, as detailed in a study published in Nature Communications.
The Phase II CheckMate 650 trial enrolled 259 patients with chemotherapy-resistant mCRPC and randomly assigned them to different treatment groups. The results revealed that immunotherapy cohorts achieved response rates of 9.3% and 19.5%, with three complete responses total. While these numbers may seem modest, they represent a genuine lifeline for patients with few alternatives. More striking was what happened in the responding patients: significant tumor shrinkage, declining prostate-specific antigen levels, and prolonged overall survival.
Yet the critical question remained: which patients would actually benefit? Not everyone with mCRPC responds to this combination, and the drugs carry real risks—treatment-related side effects of grade 3 or higher occurred in 18.4 to 34.7% of patients, with diarrhea, enterocolitis, and hypophysitis being most common. Two patients died from treatment-related complications.
This is where Sharma's team made their crucial discovery. Using the Allison Institute's immunotherapy platform, researchers analyzed tumor tissue samples from patients before treatment, comparing those who responded exceptionally well to those who didn't. Through a technique called spatial profiling, they identified specific clusters of immune cells present at higher density in the patients who benefitted most. More importantly, they found a genetic signature—a distinctive pattern of gene expression within these immune cell neighborhoods—that correlated with exceptional response and prolonged survival.
This biomarker could transform how doctors approach these patients. Rather than exposing everyone to a treatment that only helps some and harms others, physicians may soon be able to analyze a patient's tumor tissue before starting therapy to determine whether that person is likely to benefit from combination immunotherapy or whether an alternate approach would be wiser. The genetic signature essentially acts as a predictor, answering one of oncology's most pressing questions: who gets this treatment?
The combination studied remains investigational and awaits FDA approval. But Sharma and his colleagues are already planning larger, prospective studies to confirm that this biomarker reliably identifies responsive patients. For men with chemotherapy-resistant prostate cancer—a disease with what researchers call a "high unmet medical need"—this represents a meaningful step toward precision medicine. The goal is no longer one-size-fits-all immunotherapy, but rather matching the right patients to the right treatment before they ever begin.